Abiomed’s fiscal Q3 crushes The Street despite $19m tax hit

Abiomed (NSDQ:ABMD) topped the consensus forecast for its fiscal third-quarter results despite taking a nearly $19 million hit due to the tax reforms enacted last year.

The Danvers, Mass.-based cardiac assist device maker posted profits of $13.4 million, or 29¢ per share, on sales of $154.0 million for the three months ended Dec. 31, 2017, for a bottom-line slide of -12.9% on sales growth of 34.3%.

But excluding the $18.8 million tax reform hit, adjusted earnings per share were 70¢, 19¢ ahead of Wall Street, where analysts were looking for sales of $148.5 million.

“It is an exciting time for the company as we collaborate with our customers to improve patient outcomes and the standard of care for circulatory support,” chairman, president & CEO Michael Minogue said in prepared remarks. “The field of heart recovery is growing and Abiomed is well-positioned to capture the $5 billion U.S. market opportunity, while planting the seeds for future growth in global markets.”

Abiomed raised its top-line outlook to $583 million, up from prior guidance for $565 million to $575 million, which works out to a $164 million projection for fiscal Q4.

ABMD shares were up 1.3% to $238.00 apiece today in pre-market trading.

Building Better Companies at DeviceTalks Minnesota DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as: Navigating the path to market Reimbursement Winning regulatory approval Corporate culture Entering global markets Leadership Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code SAVE15 to save 15%! REGISTER NOW